V. Santini

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Xingmin Feng, N. Daver, L. Adès, 2024, HemaSphere.

MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers

Pierandrea Morandini, V. Savevski, I. Prada-Luengo, 2024, JCO clinical cancer informatics.

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

R. Bejar, U. Borate, J. Giesinger, 2024, HemaSphere.